Real-World Cost of Treatment for Multiple Sclerosis Patients Initiating and Receiving Infused Disease-Modifying Therapies Per Recommended Label in the United States

Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2020.1761821
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Informa UK Limited

Related search

PND61 Impact of Patient Cost-Sharing Arrangements for Disease Modifying Therapies on Treatment Compliance Among Patients With Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States

Advances in Therapy
MedicinePharmacology
2019English

Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Real World Treatment Patterns of Patients With Ovarian Cancer Receiving First Line Chemotherapy in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy